公开(公告)号：KR840001287B1

公开(公告)日：1984-09-07

申请号：KR840002710

申请日：1984-05-18

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UEDA IKUO ,  NAGANO MASANOBU ,  KATO MASAYUKI

IPC: C07D239/86 ,  C07D487/04 ,  C07D487/14

公开(公告)号：KR840001315B1

公开(公告)日：1984-09-11

申请号：KR840002711

申请日：1984-05-18

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UEDA IKUO ,  KATO MASAYUKI ,  NAGANO MASANOBU

IPC: C07D239/86 ,  C07D487/04 ,  C07D487/14

公开(公告)号：KR840001040B1

公开(公告)日：1984-07-26

申请号：KR840002712

申请日：1984-05-18

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UEDA IKUO ,  NAGANO MASANOBU ,  KATO MASAYUKI

IPC: C07D239/86 ,  C07D487/04 ,  C07D487/14

公开(公告)号：KR840000239B1

公开(公告)日：1984-03-07

申请号：KR810000240

申请日：1981-01-27

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UEDA IKUO ,  MATSUO MASAAKI ,  KITAURA YOSHIHIKO ,  NOBUKIYO KONISHI

IPC: C07C59/68

公开(公告)号：US3928356A

公开(公告)日：1975-12-23

申请号：US30639472

申请日：1972-11-14

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UMIO SUMINORI ,  UEDA IKUO ,  SATO YOSHINARI ,  MAENO SHIZUO

IPC: C07D233/36 ,  C07D295/15 ,  C07D313/14 ,  C07D337/14 ,  C07D409/04 ,  C07D295/04

CPC classification number: C07D295/15 ,  C07D233/36 ,  C07D313/14 ,  C07D337/14 ,  C07D409/04

Abstract: Tricyclic enamine compounds of the formula:

WHEREIN A is oxy, thio, lower alkylimino, or ethylidene; one of X1 and X2 is hydrogen and the other is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, lower alkanesulfonyl, lower alkylsulfamoyl, di(lower)alkylsulfamoyl, lower alkanoylamino, trifluoromethyl, nitro or amino; X3 is hydrogen, lower alkyl or phenyl(lower)alkyl and Nz is a 5 to 7-membered cyclic amino group. These compounds are useful as psychotropic agents, particularly as tranquilizers.

Abstract translation: 三环烯胺化合物的分子式如下：

公开(公告)号：US3625974A

公开(公告)日：1971-12-07

申请号：US3625974D

申请日：1968-04-18

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UMIO SUMINORI ,  UEDA IKUO

IPC: C07D281/14 ,  C07D281/16 ,  C07D417/06 ,  A61K27/00 ,  C07D93/42

CPC classification number: C07D417/06 ,  C07D281/14 ,  C07D281/16

Abstract: Compounds of the formula

WHEREIN EACH OF X1 and X2 is hydrogen or halogen; R1 is alkyl, haloalkyl, aralkyl or alkyl substituted with R3 in which R3 is amino, alkylamino, dialkylamino; and R2 is hydrogen, alkyl, haloalkyl, aralkyl or alkyl substituted with R3 in which R3 is the same meaning as defined above, provided that either R1 or R2 should be alkyl substituted with R3. These compounds possess potent antireserpinelike activity which makes them useful as an antidepressant.

公开(公告)号：EP0206769A2

公开(公告)日：1986-12-30

申请号：EP86304723

申请日：1986-06-19

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UEDA IKUO ,  NIWA MINEO ,  SAITO YOSHIMASA ,  YAMADA HISASHI ,  ISHII YOSHINORI

IPC: A61K35/34 ,  A61K38/22 ,  A61P7/10 ,  A61P9/12 ,  C07K14/00 ,  C07K14/575 ,  C07K14/58 ,  C07K19/00 ,  C12N1/20 ,  C12N1/21 ,  C12N15/09 ,  C12N15/16 ,  C12N15/62 ,  C12N15/70 ,  C12P21/02 ,  C12R1/19

CPC classification number: C12N15/70 ,  C07K14/58 ,  C07K2319/00 ,  C07K2319/32 ,  C07K2319/50 ,  C07K2319/75

Abstract: A process for the production of a-human atrial natriuretic polypeptide (a-hANP) involves firstly culturing a microorganism which has been transformed with an expression vector comprising a synthetic gene encoding the amino acid sequence of a protective peptide-fused a-hANP in a culture medium.
Subsequently recovering the protective peptide-fused a-hANP from the culture broth and then removing the protective peptide part from the peptide-fused polypeptide.
In addition to the process itself, chemically synthesised genes for a-hANP and protective peptide-fused a-hANP are also described together with the corresponding recombinant vectors and transformants comprising the same.
a-hANP is known to be useful as an antihypertensive diuretic agent.

公开(公告)号：JPH05345797A

公开(公告)日：1993-12-27

申请号：JP15349392

申请日：1992-06-12

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UEDA IKUO ,  NIWA MINEO ,  SAITO YOSHIMASA ,  SATO SUSUMU ,  ONO HIROKI ,  KITAGUCHI TADASHI

IPC: C07K1/12 ,  C07K14/00 ,  C07K14/57 ,  C07K14/575 ,  C07K14/65 ,  C07K19/00 ,  C12N1/21 ,  C12N15/09 ,  C12N15/71 ,  C12P21/02 ,  C12R1/19 ,  C07K13/00 ,  C07K7/10

Abstract: PURPOSE:To effectively produce an IGF-I by using a protecting peptide-fused IGF-I as the precursor for production of IGF-I. CONSTITUTION:This protecting peptide-fused IGF-I has a structure in which IGF-I is fused with a protecting peptide composed of a protein peptide having a methionine as the terminal amino acid through the methionine of the protein peptide. This protecting peptide-fused IGF-I has an amino acid sequence preferably represented by the formula and can be obtained by transforming a microorganism using a plasmid containing a gene coding the protecting peptide-fused insulin-like growth factor I, culturing the transformat in a culture medium and collecting the protecting peptide-fused insulin-like growth factor I from the culture solution.

公开(公告)号：JPH055840B2

公开(公告)日：1993-01-25

申请号：JP5551485

申请日：1985-03-18

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UEDA IKUO ,  NIWA MINEO ,  SAITO YOSHIMASA ,  SATO SUSUMU ,  ONO HIROKI ,  KITAGUCHI TADASHI

IPC: C12N15/09 ,  C07H21/04 ,  C07K1/12 ,  C07K1/20 ,  C07K14/00 ,  C07K14/575 ,  C07K14/65 ,  C07K19/00 ,  C12N1/00 ,  C12N15/00 ,  C12P20060101 ,  C12P21/02 ,  C12R1/19

公开(公告)号：JPH0359075B2

公开(公告)日：1991-09-09

申请号：JP20876686

申请日：1986-09-04

Applicant: FUJISAWA PHARMACEUTICAL CO

Inventor： UEDA IKUO ,  TAKATANI TAKAO ,  MASUGI TAKASHI ,  KOBAYASHI MASAKAZU ,  TAKASUGI HISASHI ,  KAWACHI HIROMU ,  KITAGUCHI TADASHI

IPC: C07D501/04 ,  A61K31/545 ,  A61K31/546 ,  A61P31/04 ,  C07C67/00 ,  C07C239/00 ,  C07C251/32 ,  C07D317/00 ,  C07D317/30 ,  C07D501/06 ,  C07D501/14 ,  C07D501/20 ,  C07D501/22 ,  C07D501/59